Please wait while the formulary information is being retrieved.
GANCICLOVIR SODIUM (GANCICLOVIR SODIUM)
- CMV retinitis in AIDS patients
- CMV retinitis in immunocompromised patients
- Prevention of CMV disease after organ transplant
- Ganciclovir Sodium Intravenous Powder For Solution
- Ganciclovir Intravenous Solution
- Cytovene Intravenous Solution
- By Indication
500 mg intravenous solution
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours
500 mg intravenous solution
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours
500 mg intravenous solution
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours
CMV retinitis in AIDS patients
- Infuse 5 mg/kg over 1 hour(s) by intravenous route once daily 7 days per week
- Infuse 6 mg/kg over 1 hour(s) by intravenous route once daily 5 days per week
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours for14 days
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours for21 days
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours for14-21 days
CMV retinitis in immunocompromised patients
- Infuse 5 mg/kg over 1 hour(s) by intravenous route once daily 7 days per week
- Infuse 6 mg/kg over 1 hour(s) by intravenous route once daily 5 days per week
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours for14 days
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours for21 days
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours for14-21 days
Prevention of CMV disease after organ transplant
- Infuse 5 mg/kg over 1 hour(s) by intravenous route once daily 7 days per week
- Infuse 6 mg/kg over 1 hour(s) by intravenous route once daily 5 days per week
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours for21 days
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours for7 days
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours for5 days
- Infuse 5 mg/kg over 1 hour(s) by intravenous route once daily
- Infuse 5 mg/kg over 1 hour(s) by intravenous route once daily (until 100 days post-transplantation)
- Infuse 5 mg/kg over 1 hour(s) by intravenous route once daily 7 days per week (until 100-120 days post-transplantation)
- Infuse 6 mg/kg over 1 hour(s) by intravenous route once daily 5 days per week (until 100-120 days post-transplantation)
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours for5-7 days
- Infuse 5 mg/kg over 1 hour(s) by intravenous route every 12 hours for7-14 days
- None
Contraindicated
- abacavir-lamivudine-zidovudine
- clozapine
- Clozaril
- Combivir
- deferiprone
- Fazaclo
- Ferriprox
- imipenem-cilastatin
- lamivudine-zidovudine
- Primaxin Iv
- Retrovir
- Trizivir
- Versacloz
- zidovudine
Severe
Moderate
- Atripla
- Complera
- efavirenz-emtricitabin-tenofov
- elvitegr-cobicist-emtric-tenof
- emtricitab-rilpivirine-tenofov
- emtricitabine-tenofovir
- Stribild
- tenofovir disoproxil fumarate
- Truvada
- Viread
- Lactating mother
Contraindicated
- Anemia
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Neutropenic disorder
- Thrombocytopenic disorder
Severe
Moderate
- Kidney disease with likely reduction in GFR
GANCICLOVIR SODIUM (GANCICLOVIR SODIUM)
- CMV retinitis in AIDS patients
- CMV retinitis in immunocompromised patients
- Prevention of CMV disease after organ transplant
- Anemia
- Bacterial sepsis
- Drug fever
- Dyspnea
- Granulocytopenic disorder
- Neutropenic disorder
- Acute abdominal pain
- Anorexia
- Cough
- Diarrhea
- General weakness
- Hyperhidrosis
- Nausea
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Allergic dermatitis
- Altered mental status
- Infection
- Kidney disease with reduction in GFR
- Mood changes
- Thrombocytopenic disorder
- Chills
- Peripheral neuropathy
- Pruritus of skin
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acidosis
- Agranulocytosis
- Anaphylaxis
- Biliary calculus
- Bronchospastic pulmonary disease
- Candidiasis
- Cardiac arrest
- Cardiac arrhythmia
- Cataracts
- Cerebrovascular accident
- Chest pain
- Cholestasis
- Drug-induced psychosis
- Exfoliative dermatitis
- Extrapyramidal disease
- Gastrointestinal perforation
- Gastrointestinal ulcer
- Hearing loss
- Hematuria
- Hemolytic anemia
- Hemolytic uremic syndrome
- Hepatic failure
- Hepatitis
- Hypercalcemia
- Hypertension
- Hyponatremia
- Hypotension
- Macular retinal edema
- Multiple organ failure
- Muscle weakness
- Pancreatitis
- Pancytopenia
- Peripheral ischemia
- Pulmonary fibrosis
- Renal failure
- Rhabdomyolysis
- Seizure disorder
- Skin rash
- Stevens-johnson syndrome
- Torsades de pointes
- Vasculitis
- Ventricular tachycardia
- Visual changes
Less Severe
- Abdominal distension
- Acute confusion
- Alopecia
- Aphthous stomatitis
- Arthralgias
- Arthritis
- Back pain
- Conjunctivitis
- Constipation
- Cramps in legs
- Depression
- Dizziness
- Dream disorder
- Drowsy
- Dry eye
- Dry skin
- Dysesthesia
- Dysgeusia
- Dyspepsia
- Dysphagia
- Dysphasia
- Earache
- Edema
- Eructation
- Facial palsy
- Female infertility
- Flatulence
- Hallucinations
- Headache disorder
- Hypertriglyceridemia
- Hypesthesia
- Injection site sequelae
- Insomnia
- Irritability
- Loss of sense of smell
- Malaise
- Memory impairment
- Myalgias
- Oligospermia
- Paresthesia
- Phlebitis after infusion
- Symptoms of anxiety
- Testicular atrophy
- Tinnitus
- Tremor
- Urticaria
- Vasodilation of blood vessels
- Weight loss
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Ganciclovir
- Severity Level:
2
- Additional Notes: Insufficient human data;consider maternal benefit vs poss fetal adv effects
Contraindicated
Ganciclovir
Potential for serious adverse effects
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Potential for serious adverse effects |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Ganciclovir
Renal-Adjust dose for CrCL < 70 mL/min.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Ganciclovir can decrease bone marrow function. This serious, possibly life-threatening side effect may lead to a low number of blood cells such as red cells, white cells, and platelets. This effect can cause anemia, decrease your body's ability to fight an infection, and cause bleeding problems.<br /><br />Your doctor will check the results of your blood tests and adjust your treatment to reduce your risk for these side effects. Seek immediate medical attention if you develop signs of anemia (such as unusual tiredness, fast breathing, pale skin, fast heartbeat), signs of infection (such as fever, chills, cough, persistent sore throat), and signs of bleeding (such as easy bruising/bleeding, nose bleeds, bleeding gums, bloody/black/tarry stools, vomit that looks like coffee grounds). Ganciclovir may reduce fertility in men and women.<br /><br />It may also harm an unborn baby. Talk to your doctor for more details. Ganciclovir has caused tumors in laboratory animals.<br /><br />Although there is no information in humans, ganciclovir should be considered cancer-causing (carcinogenic). See also How to Use and Precautions sections.
| CMV retinitis in AIDS patients | |
| B25.9 | Cytomegaloviral disease, unspecified |
| H32 | Chorioretinal disorders in diseases classified elsewhere |
| CMV retinitis in immunocompromised patients | |
| B25.9 | Cytomegaloviral disease, unspecified |
| H32 | Chorioretinal disorders in diseases classified elsewhere |
| Prevention of CMV disease after organ transplant | |
| Z94.0 | Kidney transplant status |
| Z94.1 | Heart transplant status |
| Z94.2 | Lung transplant status |
| Z94.4 | Liver transplant status |
| Z94.5 | Skin transplant status |
| Z94.6 | Bone transplant status |
| Z94.81 | Bone marrow transplant status |
| Z94.82 | Intestine transplant status |
| Z94.83 | Pancreas transplant status |
| Z94.84 | Stem cells transplant status |
| 0-9 | A-Z |
|---|---|
| B25.9 | Cytomegaloviral disease, unspecified |
| B25.9 | Cytomegaloviral disease, unspecified |
| H32 | Chorioretinal disorders in diseases classified elsewhere |
| H32 | Chorioretinal disorders in diseases classified elsewhere |
| Z94.0 | Kidney transplant status |
| Z94.1 | Heart transplant status |
| Z94.2 | Lung transplant status |
| Z94.4 | Liver transplant status |
| Z94.5 | Skin transplant status |
| Z94.6 | Bone transplant status |
| Z94.81 | Bone marrow transplant status |
| Z94.82 | Intestine transplant status |
| Z94.83 | Pancreas transplant status |
| Z94.84 | Stem cells transplant status |
Formulary Reference Tool